|
Identifying and Managing Prurigo Nodularis
|
|
Facebook
LinkedIn
E-Mail
|
(2983)
Other: Assessment, Autoimmune, Best Practices, Complementary, Culturally Competent Care, Dermatology, Diagnosis, Evaluation (Follow-up), Evidence-Based Guidelines, Inflammation, Pharmacology, Primary Care, Treatment, Treatment Plan
(show less)
|
Released: 08/21/2023 Expires: 08/31/2024 (subject to change)
- CE for this activity will not be available after this date.
Overview
Until recently, no therapies were specifically approved for the treatment of prurigo nodularis (PN), and clinical management relied on the off-label use of anti-inflammatory, anesthetic, and neural therapies to relieve itch, with varying degrees of evidence supporting their use. Given the nonspecific nature of these treatments, however, off-target effects are common, and side effects can be a significant burden to patients already experiencing a high degree of distress. However, as the molecular drivers of inflammation and pruritis in PN have begun to be illuminated, a variety of new and investigational therapies are being evaluated for use in PN. In September 2022, dupilumab became the first FDA-approved treatment option for PN, paving the way for a new era of disease-modifying treatments in this underserved therapeutic area. NPs and other front-line providers completing this activity will be able to distinguish PN from other dermatological conditions, identify key immune modulators and develop an evidence-based plan to care for patients suffering from this disease. Objectives - Distinguish the signs and symptoms of PN across diverse patient populations.
- Differentiate the role of key immunomodulators in the pathogenesis of PN concerning pruritus, inflammation, epithelial dysregulation, and fibrosis.
- Develop personalized and evidence-based PN treatment strategies that integrate current and emerging therapies.
Speakers Margaret Bobonich, DNP, FNP-C, DCNP, FAANP Leigh Ann Pansch, MSN, FNP-BC, DCNP
Disclosure This program was planned in accordance with AANP CE Standards and Policies.The speakers have the following disclosures: - Margaret Bobonich
- Consultant/Speaker’s bureau: Lilly USA (psoriasis and alopecia), Bristol Myers Squibb (psoriasis)
- Advisory Board: Lilly USA (psoriasis and alopecia), AbbVie (psoriasis, hidradenitis suppurativa, and atopic dermatitis), Bristol Myers Squibb (psoriasis), Dermavant (psoriasis), Incyte (vitiligo), Novartis (psoriasis), Boehringer Ingelheim (psoriasis), Biofrontera (atopic dermatitis), UCB (psoriasis)
- Leigh Ann Pansch
- Abbvie: Speaker Atopic Dermatitis
- Arcutis: Speaker Psoriasis
- BMS: Speaker Psoriasis
- Beiersdorf: Speaker Eucerin/Aquaphor
- Dermavant: Speaker Psoriasis
- Galderma: Speaker Acne, Rosacea
- Janssen: Speaker Psoriasis/PSA
- Leo: Consultant Atopic Dermatitis
- Lilly: Speaker Psoriasis, Alopecia Areata
- Novartis: Consultant Hidradenitis Suppurativa
- Pfizer: Speaker Psoriasis
- Regeneron/Sanofi: Speaker Atopic Dermatitis, Prurigo Nodularis
- UCB: Speaker Psoriasis
All relevant financial relationships have been mitigated.All Planners involved in this activity have no relevant financial relationships to disclose.This activity is supported by an educational grant from Galderma. Accreditation Information This activity is approved for 1.00 contact hours of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners®. Activity ID #23086267. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 9/1/2023 to 8/31/2024 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201975. Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content:
- Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test. A passing score of 70%+ is required. Learners will have 4 attempts to pass.
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1 Contact Hour(s) of CE, 0.33 of which may be applied towards Pharmacology
|
|
|
|